Glenmark Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 277.00 Cr
as on 24-10-2024
- Paid Up Capital ₹ 28.22 Cr
as on 24-10-2024
- Company Age 47 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 890.00 Cr
as on 24-10-2024
- Satisfied Charges ₹ 1,040.00 Cr
as on 24-10-2024
- Revenue 5.14%
(FY 2023)
- Profit -39.49%
(FY 2023)
- Ebitda -12.76%
(FY 2023)
- Net Worth 6.80%
(FY 2023)
- Total Assets 7.29%
(FY 2023)
About Glenmark Pharmaceuticals
It is listed on the Bombay Stock Exchange(BSE) under the ticker symbol 532296 and on the National Stock Exchange(NSE) under GLENMARK.
The Corporate was formerly known as Glenmark Pharmaceuticals Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 277.00 Cr and a paid-up capital of Rs 28.22 Cr.
The company currently has active open charges totaling ₹890.00 Cr. The company has closed loans amounting to ₹1,040.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Glenmark Pharmaceuticals Limited India are V Mani as CFO and Harish Kuber as Company Secretary. Blanche Elizabeth, Rajesh Desai, Glenn Saldanha, and Five other members serve as directors at the Company.
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Glenmark Pharmaceuticals Limited offer?
Glenmark Pharmaceuticals Limited offers a wide range of products and services, including Baby Care, Baby Skin Care, Ayurveda Products, Natural Hair & Skin Care, Hair Care, Hair Conditioners, Skin Care, Acne Care, Vitamins & Supplements, Multivitamins.
Who are the key members and board of directors at Glenmark Pharmaceuticals?
Executive Team (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Glenn Saldanha  | Managing Director | 12-Oct-1998 | Current |
| V Mani | CFO | 16-Nov-2017 | Current |
| Harish Kuber | Company Secretary | 02-Feb-2017 | Current |
Board Members(7)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Vijayalakshmi Iyer | Director | 14-Apr-2023 | Current |
Dipankar Bhattacharjee  | Director | 14-Aug-2020 | Current |
| Blanche Elizabeth | Director | 17-Dec-1977 | Current |
| Rajesh Desai | Director | 16-May-2002 | Current |
| Cherylann Pinto | Whole-Time Director | 16-May-2007 | Current |
| V Mani | Whole-Time Director and Cfo | 29-May-2018 | Current |
Financial Performance and Corporate Structure Insights of Glenmark Pharmaceuticals.
Glenmark Pharmaceuticals Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 5.14% increase. The company also saw a substantial fall in profitability, with a 39.49% decrease in profit. The company's net worth moved up by a moderate rise of 6.8%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Glenmark Pharmaceuticals?
In 2022, Glenmark Pharmaceuticals had a promoter holding of 46.65% and a public holding of 53.35%. The company had 1 Subsidiary. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Computer Age Management Services LimitedActive 36 years 6 monthsVijayalakshmi Iyer is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Bank Of India Creation Date: 21 May 1985 | ₹890.00 Cr | Open |
Bank Of India Creation Date: 29 Jul 2009 | ₹60.00 Cr | Satisfied |
Axis Bank Limited Creation Date: 18 Jun 2009 | ₹75.00 Cr | Satisfied |
How Many Employees Work at Glenmark Pharmaceuticals?
Glenmark Pharmaceuticals has a workforce of 12427 employees as of Aug 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Glenmark Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Glenmark Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
